Planta Med 2014; 80(07): 577-582
DOI: 10.1055/s-0034-1368354
Natural Product Chemistry
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Lipase Inhibition and Antiobesity Effect of Atractylodes lancea

Ping Jiao
1   Unigen USA, Seattle, WA, USA
,
Julie Tseng-Crank
1   Unigen USA, Seattle, WA, USA
,
Brandon Corneliusen
1   Unigen USA, Seattle, WA, USA
,
Mesfin Yimam
1   Unigen USA, Seattle, WA, USA
,
Mandee Hodges
1   Unigen USA, Seattle, WA, USA
,
Mei Hong
1   Unigen USA, Seattle, WA, USA
,
Catherine Maurseth
1   Unigen USA, Seattle, WA, USA
,
Misun Oh
2   Unigen Korea, Cheonam Si, Chungnam, South Korea
,
Hyunjin Kim
2   Unigen Korea, Cheonam Si, Chungnam, South Korea
,
Min Chu
1   Unigen USA, Seattle, WA, USA
2   Unigen Korea, Cheonam Si, Chungnam, South Korea
,
Qi Jia
1   Unigen USA, Seattle, WA, USA
2   Unigen Korea, Cheonam Si, Chungnam, South Korea
› Author Affiliations
Further Information

Publication History

received 17 December 2013
revised 06 March 2014

accepted 10 March 2014

Publication Date:
31 March 2014 (online)

Abstract

The ethanol extract of Atractylodes lancea rhizome displayed significant lipase inhibition with an IC50 value of 9.06 µg/mL in a human pancreatic lipase assay from high-throughput screening. Bioassay-guided isolation led to the identification of one new polyacetylene, syn-(5E,11E)-3-acetoxy-4-O-(3-methylbutanoyl)-1,5,11-tridecatriene-7,9-diyne-3,4-diol (7), along with six known compounds (16). The structure of compound 7 was determined based on the analysis of NMR and MS data. Among these seven lipase inhibitors, the major compound atractylodin (1) showed the highest lipase inhibitory activity (IC50 = 39.12 µM). The antiobesity effect of the ethanol extract of Atractylodes lancea rhizome was evaluated in a high-fat diet-induced obesity mice model at daily dosages of 250 mg/kg and 500 mg/kg body weight for 4 weeks, and treatment with this extract demonstrated a moderate efficacy at the 500 mg/kg dose level.

Supporting Information

 
  • References

  • 1 Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643
  • 2 Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006; 5: 919-931
  • 3 World Health Organization. Obesity. Available at http://www.who.int/topics/obesity/en/ Accessed October 10, 2013.
  • 4 Tucci SA, Boyland EJ, Halford JC. The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents. Diabetes Metab Syndr Obes 2010; 3: 125-143
  • 5 Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov 2004; 3: 695-710
  • 6 Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today 2007; 12: 879-889
  • 7 Borgström B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988; 962: 308-316
  • 8 Weibel EK, Hadvary P, Hochuli E, Kupfer E, Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot 1987; 40: 1081-1085
  • 9 Li F, Li W, Fu H, Zhang Q, Koike K. Pancreatic lipase-inhibiting triterpenoid saponins from fruits of Acanthopanax senticosus . Chem Pharm Bull 2007; 55: 1087-1089
  • 10 Sharma N, Sharma VK, Seo SY. Screening of some medicinal plants for anti-lipase activity. J Ethnopharmacol 2005; 97: 453-456
  • 11 Kim HY, Kang MH. Screening of Korean medicinal plants for lipase inhibitory activity. Phytother Res 2005; 19: 359-361
  • 12 Zheng CD, Duan YQ, Gao JM, Ruan ZG. Screening for anti-lipase properties of 37 traditional Chinese medicinal herbs. J Chin Med Assoc 2010; 73: 319-324
  • 13 Sun XY, Sun FY. Shen Nong Ben Cao Jing, 4th edition. Beijing: Shang Wu Yin Shu Guan; 1959: 13
  • 14 Gruenwald J. PDR for herbal medicines. 2nd. edition. Montvale: Thomson Physicianʼs Desk Reference, Inc.; 2000: 706-707
  • 15 Yoshioka I, Hikino H, Sasaki Y. The constituents of Atractylodes. VII. The structure of atractylodin. 2. The chromophores. Chem Pharm Bull 1960; 8: 952-956
  • 16 Yoshioka I, Hikino H, Sasaki Y. Studies on the constituents of Atractylodes. VI. The structure of atractylodin. 1. The skeleton. Chem Pharm Bull 1960; 8: 949-951
  • 17 Lehner MS, Steigel A, Bauer R. Diacetoxy-substituted polyacetylenes from Atractylodes lancea . Phytochemistry 1997; 46: 1023-1028
  • 18 Resch M, Heilmann J, Steigel A, Bauer R. Further phenols and polyacetylenes from the rhizomes of Atractylodes lancea and their anti-inflammatory activity. Planta Medica 2001; 67: 437-442
  • 19 Kano Y, Komatsu K, Saito K, Bando H, Sakurai T. A new polyacetylene compound from Atractylodes rhizome. Chem Pharm Bull 1989; 37: 193-194
  • 20 Dong H, He L, Huang M, Dong Y. Anti-inflammatory components isolated from Atractylodes macrocephala Koidz. Nat Prod Res 2008; 22: 1418-1427
  • 21 Nakai Y, Sakakibara I, Hirakura K, Terabayashi S, Takeda S. A new acetylenic compound from the rhizomes of Atractylodes chinensis and its absolute configuration. Chem Pharm Bull 2005; 53: 1580-1581
  • 22 Wang HY, Guo YW, Wang T, Cai YS, Sun P. Enyne bromide compounds as pancreatic lipase inhibitor and their preparation. Faming Zhuanli Shenqing. China Patent CN102850208 A20130102 2013
  • 23 Bitou N, Ninomiya M, Tsujita T, Okuda H. Screening of lipase inhibitors from marine algae. Lipids 1999; 34: 441-445